This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
- Investigator
- Roland Staud
- Status
- Accepting Candidates
- Ages
- 50 Years - N/A
- Sexes
- All